Clovis Oncology, Inc. (NASDAQ:CLVS) has earned an average recommendation of “Buy” from the twenty-two brokerages that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold recommendation and fourteen have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $88.61.
Several research firms have recently weighed in on CLVS. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Clovis Oncology in a report on Friday, August 18th. Leerink Swann lowered their target price on shares of Clovis Oncology to $107.00 and set an “outperform” rating on the stock in a report on Friday, August 18th. Evercore ISI began coverage on shares of Clovis Oncology in a report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 target price on the stock. Morgan Stanley lowered their target price on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating on the stock in a report on Thursday, November 2nd. Finally, Royal Bank Of Canada began coverage on shares of Clovis Oncology in a report on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 target price on the stock.
Shares of Clovis Oncology (NASDAQ CLVS) opened at $61.33 on Monday. The company has a current ratio of 3.19, a quick ratio of 3.16 and a debt-to-equity ratio of 0.94. Clovis Oncology has a fifty-two week low of $35.35 and a fifty-two week high of $99.45.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $84.54, for a total transaction of $253,620.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In the last three months, insiders have sold 9,000 shares of company stock worth $653,220. Insiders own 12.50% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Phocas Financial Corp. bought a new position in shares of Clovis Oncology in the 2nd quarter valued at about $112,000. Capital Analysts LLC bought a new position in shares of Clovis Oncology in the 3rd quarter valued at about $111,000. Advisors Asset Management Inc. boosted its stake in shares of Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the last quarter. Cypress Capital Management LLC WY boosted its stake in shares of Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Clovis Oncology by 284.9% in the 2nd quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 2,000 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “Clovis Oncology, Inc. (CLVS) Receives Average Rating of “Buy” from Analysts” was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2017/12/04/clovis-oncology-inc-clvs-receives-average-rating-of-buy-from-analysts.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.